文献速递其他结缔组织病

系统性硬化症相关间质性肺病候选血清生物标志物的性能评估

Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
PubMed 文献 · Arthritis Rheumatol · 2019-04-26

本研究纳入法国巴黎和挪威奥斯陆联合队列的427例系统性硬化症(SSc)患者,采用酶联免疫吸附试验检测血清SP-D、KL-6、CCL18和OX40L浓度,评估其对SSc相关间质性肺病(ILD)的诊断和预后性能。结果显示SP-D是SSc相关ILD的相关诊断生物标志物,KL-6可用于评估肺纤维化严重程度,CCL18可能是ILD进展的预测标志物。

要点

  • SP-D与肺纤维化相关(OR 3.15,95%CI 1.81-5.48,P<0.001),可作为诊断标志物
  • KL-6与FVC(r=-0.317)、DLCO(r=-0.335)及肺纤维化范围(r=0.551)相关
  • CCL18可独立预测FVC下降>10%(HR 2.90,95%CI 1.25-6.73,P=0.014)

核心结论

  • SP-D是SSc相关ILD的相关诊断生物标志物,KL-6可用于评估肺纤维化严重程度,CCL18可能是ILD进展的预测标志物。

研究设计与样本

  • 研究纳入法国巴黎和挪威奥斯陆联合队列的427例SSc患者,采用酶联免疫吸附试验检测血清SP-D、KL-6、CCL18和OX40L浓度。
  • 通过高分辨率计算机断层扫描和肺功能测试测量肺纤维化,评估候选生物标志物与基线疾病累及及疾病进展的关联(平均随访3.2±4.4年)。

主要发现

  • 基线时SSc患者血清KL-6水平与用力肺活量(FVC)(r=-0.317,P<0.001)、一氧化碳弥散量(r=-0.335,P<0.001)及肺纤维化范围(r=0.551,P<0.001)相关。
  • 多变量分析中,血清KL-6和SP-D水平与肺纤维化相关(OR 2.41,95%CI 1.43-4.07,P=0.001;OR 3.15,95%CI 1.81-5.48,P<0.001),而CCL18和OX40L无此关联。
  • 基线有ILD的SSc患者中,纵向多变量分析显示血清CCL18水平是FVC下降>10%(HR 2.90,95%CI 1.25-6.73,P=0.014)和新发广泛性疾病(HR 3.71,95%CI 1.02-13.52,P=0.048)的独立预测因子。
  • 构建的矩阵式逻辑回归模型根据血清SP-D水平(用于诊断)和CCL18水平(用于疾病进展)可区分肺纤维化诊断或恶化的三个风险组(轻度、中度或高度)。

关键数值与推荐

  • SP-D与肺纤维化诊断的OR为3.15(95%CI 1.81-5.48,P<0.001)。
  • KL-6与肺纤维化诊断的OR为2.41(95%CI 1.43-4.07,P=0.001)。
  • CCL18预测FVC下降>10%的HR为2.90(95%CI 1.25-6.73,P=0.014)。
  • CCL18预测新发广泛性疾病的HR为3.71(95%CI 1.02-13.52,P=0.048)。

临床怎么用

  • SP-D可用于SSc相关ILD的诊断评估,KL-6可用于评估肺纤维化严重程度。
  • CCL18可用于预测基线有ILD的SSc患者的疾病进展风险。
  • 基于SP-D和CCL18的矩阵式逻辑回归模型可辅助区分肺纤维化诊断或恶化的风险组。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interstitial lung disease (ILD) in systemic sclerosis (SSc) runs a highly variable course, and prediction tools are highly desired. The aim of this study was to assess the diagnostic and prognostic performance of 4 candidate serum biomarkers for SSc-associated ILD. METHODS: Serum samples from a combined cohort of SSc patients (from Paris, France and Oslo, Norway; n = 427) were analyzed by enzyme-linked immunosorbent assay for concentrations of lung epithelial-derived surfactant protein D (SP-D), Krebs von den Lungen 6 glycoprotein (KL-6), CCL18, and OX40 ligand (OX40L). Lung fibrosis was measured by high-resolution computed tomography and pulmonary function tests. Associations of these candidate biomarkers with baseline disease involvement and prediction of disease progression over time (mean ± SD follow-up 3.2 ± 4.4 years) were investigated. RESULTS: In SSc patients at baseline, serum levels of KL-6 correlated with the forced vital capacity (FVC) (r = -0.317, P < 0.001), diffusing capacity for carbon monoxide (r = -0.335, P < 0.001), and extent of lung fibrosis (r = 0.551, P < 0.001). In multivariate analyses, serum levels of KL-6 and SP-D, but not CCL18 and OX40L, were associated with lung fibrosis (odds ratio [OR] 2.41, 95% confidence interval [95% CI] 1.43-4.07 [P = 0.001] and OR 3.15, 95% CI 1.81-5.48 [P < 0.001], respectively). In SSc patients with ILD at baseline, longitudinal, multivariate analyses showed that CCL18 serum levels were an independent predictor of a >10% decrease in the FVC (hazard ratio [HR] 2.90, 95% CI 1.25-6.73; P = 0.014) and de novo development of extensive disease (HR 3.71, 95% CI 1.02-13.52; P = 0.048). Matrix-based logistic regression models for the diagnosis and prognosis of SSc-associated ILD were constructed, and these models discriminated 3 groups of risk (mild, moderate, or high) for the diagnosis or worsening of lung fibrosis according to the serum levels of SP-D (for diagnosis) and serum levels of CCL18 (for progression of disease). CONCLUSION: These results show that SP-D is a relevant diagnostic biomarker for SSc-associated ILD, whereas KL-6 could be used to assess the severity of lung fibrosis. CCL18 appears to be a potential predictive marker for progression of ILD in SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Elhai M, Hoffmann-Vold AM, Avouac J, et al. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2019. PMID: 30624031. doi:10.1002/art.40815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。